Regenacy Pharmaceuticals in Waltham, Massachusetts closed a $30 million Series A financing. The round was co-led by Cobro Ventures and Taiwania Capital Management Corporation. Other participants included 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, TA YA Venture Holdings and undisclosed private investors.
“We are fortunate to have the strong support of investors aligned with our mission to provide lasting relief of all symptoms of diabetic peripheral neuropathy,” said Simon Jones, Regenacy’s president and chief executive officer. “Our preclinical studies demonstrate that selectively inhibiting HDAC6 has the potential to safely restore nerve function in multiple peripheral neuropathies, and we are looking forward to advancing our lead program into Phase II studies this year.”
